Isaza MA, Marulanda M, Pérez D, Vanegas G

Language: Spanish
References: 10
Page: 69-72
PDF size: 165.25 Kb.

ABSTRACT

Leishmaniasis is an intracellular protozoan disease. One of its forms of presentation is mucocutaneous, which is sequela of cutaneous leishmania and only occurs in 1% to 5% of those who suffer it. It affects the nasal, pharyngeal and laryngeal mucosa, causing dyspnea and dysphagia. We presented a case of a 76-year-old patient with obstructive nasal symptoms, who evidenced multiple nasal and pharyngolaryngeal synechiae. Given the clinical suspicion of the disease, it is important to remember that the diagnosis is made through the Montenegro intradermal reaction and or indirect immunofluorescence titers greater than 1:16, and the treatment includes pentavalent antimonial, one of the most used; however, it has a high degree of recurrence and side effects, so amphotericin B becomes the treatment of choice. In some cases, surgical management can be very useful for the improvement of symptoms caused by the disease. Thus, mucocutaneous leishmania becomes a disease of interest for otorhinolaryngologists, who, with knowledge of its natural history, can carry out early management and adequate correction of sequelae to improve the patients’ quality of life.

REFERENCES

1. Di Lella F, Vincenti V, Zennaro D, Afeltra A, Baldi A, GiordanoD, et al. Mucocutaneous leishmaniasis: report of a case withmassive involvement of nasal, pharyngeal and laryngealmucosa. Int J Oral Maxillofac Surg. 2006;35(9):870-2. doi:10.1016/j.ijom.2006.02.015.

2. David CV, Craft N. Cutaneous and mucocutaneousleishmaniasis. Dermatol Ther. 2009;22(6):491-502. doi:10.1111/j.1529-8019.2009.01272.x.

3. Amato VS, Tuon FF, Imamura R, Abegão de Camargo R,Duarte MI, Neto VA. Mucosal leishmaniasis: description ofcase management approaches and analysis of risk factors fortreatment failure in a cohort of 140 patients in Brazil. J Eur AcadDermatol Venereol. 2009;23(9):1026-34. doi: 10.1111/j.1468-3083.2009.03238.x.

4. Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, et al.Treatment of Bolivian mucosal leishmaniasis with miltefosine.Clin Infect Dis. 2007;44(3):350-6. doi: 10.1086/510588.

5. da Costa DC, Palmeiro MR, Moreira JS, Martins AC, da SilvaAF, Madeira Mde F, et al. Oral manifestations in the Americantegumentary leishmaniasis. PLoS One. 2014;9(11):e109790.doi: 10.1371/journal.pone.0109790.

6. Guía protocolo para la vigilancia en salud pública deleishmaniasis. Ministerio de la Protección Social, InstitutoNacional de Salud; 2013. Consultado noviembre de 2020[consultado el falta la fecha en que el autor consultó el enlace].Disponible en: https://www.minsalud.gov.co/Documents/Salud%20P%C3%BAblica/Ola%20invernal/protocolo%20LEISHMANIASIS.pdf

7. Guía de atención de la leishmaniasis. Medicina & Laboratorio.2011;17(11-12):553-80.

8. Goto H, Lindoso JA. Current diagnosis and treatment ofcutaneous and mucocutaneous leishmaniasis. Expert Rev AntiInfect Ther. 2010;8(4):419-33. doi: 10.1586/eri.10.19.

9. Palumbo E. Treatment strategies for mucocutaneousleishmaniasis. J Glob Infect Dis. 2010;2(2):147-50. doi:10.4103/0974-777X.62879.

10. Goto H, Lauletta Lindoso JA. Cutaneous and mucocutaneousleishmaniasis. Infect Dis Clin North Am. 2012;26(2):293-307.doi: 10.1016/j.idc.2012.03.001. (Nota: esta referencia no tienellamado dentro del texto)